VALFIX Medical Announces Issuance of New U.S. Patent for Its Heart Valve Repair and Replacement Technology

TEL AVIV, Israel - May 13, 2019 - EntSun -- VALFIX Medical Ltd. announces the issuance of US Patent No. 10,278,820 titled "Percutaneous valve repair and replacement" issued May 7, 2017. VALFIX Medical is developing trans-catheter solutions for patients suffering from valvular heart disease and heart failure.

"It is exciting to receive this patent as it confirms our technology patentability; our technology is unique and distinct in the market," stated Eli Bar, CEO and Founder of VALFIX Medical. " This patent granted confirms and protects our core technology and adds significant value to our stakeholders"

VALFIX Medical technology is distinguished in its approach to offer both repair and replacement treatment in one procedure. This unique toolbox approach gives more options for interventional cardiologists to deliver the most effective therapy to this complex condition.

More on EntSun News

• ZEELOOL x Prabal Gurung collection: Styling High-Fashion Looks for Everyday Wear
• Physician Calls for States Nationwide to Ensure ADA Compliance in Independent Commissions
• MEDIA ADVISORY - Strengthening Children's Mental Health Across New Jersey
• NumberSquad Launches Year‑Round Tax Planning Package for Small Businesses and the Self‑Employed
• GlexScale launches a unified model for sustainable SaaS expansion across EMEA

Concurrently with the issuance of this patent, VALFIX Medical continues to develop its patent portfolio with other patents in preparation and pending.

About VALFIX Medical:

VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.

To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com

Recently, VALFIX Medical also announced the completion of its second round of investment and the recipience of a Research & Development grant from the Israeli Innovation Authority (https://www.valfixmed.com/blog).